Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

ARMOR Phase 3 Study
Jul. 14, 2023

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Read More
Jul. 10, 2023

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Read More
Jun. 1, 2023

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Read More